knowledge -WSS

knowledge

author：leisure time 2025-09-30 23:06:49 - browse：8862

Monica Bertagnolli -- Health Policy coverage from STAT — Monica Bertagnolli, the nominee to lead the National Institutes of Health Jeff Chiu/AP

Monica Bertagnolli, President Biden’s nominee to lead the National Institutes of Health, spent her confirmation hearing Wednesday stuck in the middle of Republicans’ and Democrats’ bickering over her agency’s role in high drug costs, ultimately refusing to commit to either party’s approach.

Bertagnolli similarly walked a line on government funding for gender-affirming care research and other hotly politicized health care issues, though she did stress that transgender youth are some of the country’s most vulnerable people.

The long-awaited hearing came months after Committee Chairman Bernie Sanders (I-Vt.) pledged to stall her confirmation process until Biden did more to address high drug prices, like an assurance that the NIH would insert reasonable pricing requirements into deals with commercial drugmakers.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Achieving telehealth equity for people with hearing loss

focus

WSS

Hospitals need to get ahead of regulations on climate change

Beyond aggravation: Constipation is an American epidemic

Stroke rates rising, especially in working

The untold story of TV’s first prescription drug ad

Congress: Prevent baby formula shortages by passing a new bill

U.S. death rates show how politics are affecting public health

focus

knowledge

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

For AI in health care standards, federal regulators join with industry group

Medicare proposal to cover medical devices draws a mixed reaction

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Medical records are filled with copy

State of the Union pitch: Bigger Medicare drug price negotiations

23andMe had bad news about my health. I wish a person had delivered it

Medicare drug price negotiation continues, as pharma counteroffers

Jerome Adams on the need for new antivirals for Covid

Stem cell biologist probes earliest stages of human development

Wikipedia

Hospitals need to get ahead of regulations on climate change

Lawsuit challenges CMS nursing home minimum staffing rule

He's 19 months old and has one of the world’s rarest diseases

For AI in health care standards, federal regulators join with industry group

Readout Newsletter: BridgeBio, Akero, and human embryo models

Families look for replacement for GSK asthma drug Flovent

focus

hotspot

focus

hotspot